secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001104659-24-099121
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events
--------------------------------------------------------------------------------

- VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.
- PK results showed dose-dependent exposure of VYN202 in plasma and urine across all doses tested.
- PD activity observed: increased HEXIM1 (target engagement) and inhibitory effect on inflammatory biomarkers for psoriasis and rheumatoid arthritis.
- Dosing in the multiple ascending dose (MAD) portion of Phase 1a has begun; results expected Q4 2024.
- CEO David Domzalski highlighted milestone for the company's BD2-selective BET inhibitor platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/0001104659-24-099121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/tm2423851d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-099121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer